Cure Arthritis Naturally

Beat Arthritis Naturally

Get Instant Access

Braun J, Bollow M, Neure L, et al. (1995) Use of immunohisto-logic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499-505 Catrina AI, Lampa J, Ernestam S, et al. (2002) Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 41:484489

Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907-916

Culy CR, Keating GM (2002) Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62:2493-2537 Davis JC, Jr (2005) Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin Arthritis Rheum 34:668-677 Don BR, Spin G,NestorovI, et al. (2005) The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol 57:1407-1413 Drynda S, Kuhne C, Kekow J (2002) Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Ann Rheum Dis 61:254-256 Enbrel® (etanercept) (2005) US Full Prescribing Information. Immunex Corporation, marketed by Amgen and Wyeth Pharmaceuticals, Thousand Oaks, CA, 2005 European Medicines Agency (2006) Enbrel product information. Available at: Humans/EPAR/enbrel/enbrel.htm. Accessed March, 2006 Goffe B, Cather JC (2003) Etanercept: An overview. J Am Acad

Dermatol 49:S105-111 Goldsmith DR, Wagstaff AJ (2005) Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 6:121 -136 Gottlieb AB, Chamian F, Masud S, et al. (2005) TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175:2721 -2729 Jarvis B, Faulds D (1999) Etanercept: a review of its use in rheumatoid arthritis. Drugs 57:945-966 Kavanaugh AF (2005) Macromolecule tumor necrosis factor inhibitors: are more better? J Rheumatol 32:2285-2287

Keystone EC, Schiff MH, Kremer JM, et al. (2004) Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50:353-363

Keyszer G, Lambiri I, Nagel R, et al. (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 26:251-258 Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1-23

Krueger GG, Elewski B, Papp K, et al. (2006) Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol 54:S112-119 Lee H, Kimko HC, Rogge M, et al. (2003) Population pharma-cokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348-365

Maksymowych WP, Poole AR, Hiebert L, et al. (2005) Etaner-cept exerts beneficial effects on articular cartilage biomark-ers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 32:1911 -1917 Mease P (2004) TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 63:755 -758 Moreland LW, Bucy RP, Weinblatt ME, et al. (2002) Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 103:13-21 Moreland LW, Weinblatt ME, Keystone EC, et al. (2006) Etanercept treatment in adults with established rheumatoid arthritis: 7years of clinical experience. J Rheumatol 33:854-61 NestorovI (2005) Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 74:13 -18 Nestorov I, Zitnik R, Ludden T (2004) Population pharmacoki-netic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn 31:463-490

Nickoloff BJ, Stevens SR (2006) What have we learned in dermatology from the biologic therapies? J Am Acad Dermatol 54:S143 -151

Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis.

N Engl J Med 350:2167-2179 Ostensen M, Eigenmann GO (2004) Etanercept in breast milk.

J Rheumatol 31:1017- 1018 Partsch G, Steiner G, Leeb BF, et al. (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24:518-523

Ritchlin C, Haas-Smith SA, Hicks D, et al. (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25:1544-1552

Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821 - 831 Saxne T, Palladino MA, Jr, Heinegard D, Talal N, Wollheim FA (1988) Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041 -1045 Schön MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899-1912

Schotte H, Schluter B, Willeke P, et al. (2004) Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 43:960-964 Strober BE (2005) The treatment of psoriasis with etanercept.

Semin Cutan Med Surg 24:28-36 Tyring S, Gottlieb A, Papp K, et al. (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: doubleblind placebo-controlled randomised phase III trial. Lancet 367:29-35

van der Linden S, van der Heijde D, Braun J (2005) Ankylosing spondylitis. In: Harris EJ, Budd R, Firestein GS, et al. (eds) Kelly's textbook of rheumatology. Elsevier Saunders, Philadelphia, pp 1125-1141 Yim DS, Zhou H, Buckwalter M, et al. (2005) Population phar-macokinetic analysis and simulation ofthe time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 45:246-256 Zhou H (2005) Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45:490-497 Zhou H, Mayer PR, Wajdula J, Fatenejad S (2004a) Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 44:1235-1243

Zhou H, Buckwalter M, Boni J, et al. (2004b) Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42:267-276

Was this article helpful?

0 0
Arthritis Joint Pain

Arthritis Joint Pain

Arthritis is a general term which is commonly associated with a number of painful conditions affecting the joints and bones. The term arthritis literally translates to joint inflammation.

Get My Free Ebook

Post a comment